Chesnara Plc (LON:CSN) is the topic of conversation when Dr Brian Moretta joins DirectorsTalk Interviews.
Brian talks us through his recent note on the company entitled ‘Good first half, aided by markets and acquisitions’, taking us through the main features, the factors driving an improvement in Economic Value, operational improvements compared with 2022, its greater emphasis on acquisitions and its cash generation and dividends.
Chesnara plc (LON:CSN) is the topic of conversation when Hardman & Co’s Financial Analyst Dr Brian Moretta caught up with DirectorsTalk for an exclusive interview. Q1: Chesnara recently announced its 2024 interim results, what were the
Chesnara plc (LON:CSN) is the topic of conversation when Hardman & Co Analyst Dr Brian Moretta joins DirectorsTalk. In this interview with Brian Moretta, Analyst at Hardman & Co, key insights are provided on Chesnara Plc following
Chesnara plc (LON:CSN) is the topic of conversation when Hardman & Co’s Financial Analyst Dr Brian Moretta caught up with DirectorsTalk for an exclusive interview. Q1: Chesnara recently announced its 2023 results. What were the main
Chesnara plc (LON:CSN) is the topic of conversation when Dr. Brian Moretta joins DirectorsTalk Interviews. Dr. Brian Moretta, Head of Tax-Enhanced Services & Financial Analyst at Hardman & Co, delves into Chesnara plc’s impressive 2023 financial results.
Chesnara Plc (LON:CSN) has announced its 2023 results. Positive returns from equity markets and gains from acquisitions in the first half were somewhat offset by adverse changes to operating assumptions in the second. Economic Value profit of
Hardman and Co’s Dr Brian Moretta discusses Chesnara in this exclusive interview with DirectorsTalk.
Chesnara plc (LON:CSN) has announced its 2023 interim results. Good returns in equity markets, most notably in Sweden, and the benefit from acquisitions meant earnings were well ahead of our normalised estimates. Economic Value profit was
Chesnara plc (LON:CSN) has announced its first acquisition of 2023. It is buying the onshore protection business from Canada Life’s UK business. This consists of 47,000 term assurance and critical illness policies. Chesnara is paying £9m
Hardman and Co’s Dr Brian Moretta discusses Chesnara plc in this exclusive interview with DirectorsTalk.
Chesnara plc (LON:CSN) is the topic of conversation when Dr Brian Moretta Analyst at Hardman & Co talks us though his latest note entitled ‘Great cashflow in tough markets’. Brian takes us through the key points of
Chesnara plc (LON:CSN) has announced its 2022 results. With weak equity markets and rising interest rates and credit spreads, the risk asset exposure weighed on results. Economic Value profit came in at a loss of £106.1m,
Chesnara plc (LON:CSN) has announced its 2022 half-year results. With weak equity markets and rising interest rates and credit spreads, the risk asset exposure weighed on results. Economic Value profit came in at a loss of
Hardman and Co’s Dr Brian Moretta discusses Chesnara plc in this exclusive interview with DirectorsTalk.
Chesnara plc (LON: CSN) is the topic of conversation when Dr Brian Moretta, Analyst at Hardman & Co joins DirectorsTalk Interviews. Brian discusses its recent acquisition in the Netherlands, a life insurer known as Conservatrix, the background
Chesnara plc (LON:CSN) has announced its seventh acquisition in the Netherlands, buying the closed life insurance books of “Conservatrix”. The latter is a life insurance and mortgage provider that filed for bankruptcy at the end of
Chesnara plc (LONCSN) has announced its seventh acquisition in the Netherlands, buying the closed life insurance books of “Conservatrix”. The latter is a life insurance and mortgage provider that filed for bankruptcy at the end of
Hardman and Co’s Dr Brian Moretta discusses Chesnara plc in this exclusive interview with DirectorsTalk.
Chesnara plc (LON:CSN) is the company of discussion when Dr Brian Moretta, Analyst at Hardman & Co joins DirectorsTalk Interviews. In this interview Brian explains how the company performed over the full year, discusses the operational challenges,
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.